Management of Potential Drug Interactions in Community Pharmacies: a Questionnaire-based Survey in Switzerland

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2007 Jan 12

PMID 17216436

Citations 11

Authors

Jorg Indermitte

Laura Erba

Marianne Beutler

Rudolf Bruppacher

Walter E Haefeli

Kurt E Hersberger

Affiliations

Soon will be listed here.

Abstract

Objective: To analyze the current drug-interaction management in Swiss community pharmacies, with a particular focus on electronic systems, and to compare the results with those expressed by German general practitioners in a recent survey.

Methods: Data were collected with a postal questionnaire which was randomly sent to 500 out of 833 community pharmacies in the German part of Switzerland.

Results: The response rate was 57.4%, and only 24.7% pharmacists reported that they were confronted less than daily with potential drug interactions. Use of computer software to identify potential drug interactions was widespread in community pharmacies (90.2%), and the software was the primary source of information (81.2 +/- 29.6%). The quality of the interaction software was judged sensitive (identifying all dangerous interactions) by 80.5 +/- 21.5%, but specific (identifying only relevant interactions) by only 38.3 +/- 32%. Pharmacists declared a low override rate (14%) of drug interaction alerts, although unjustified alerts were reported by 60.6 +/- 33.1%. In contrast to general practitioners, pharmacists opted less often for information on the mechanism of the interaction, and more frequently for details for dose adjustment. Both groups complained about deficient information on non-interacting alternatives.

Conclusion: The information needs of community pharmacists differed considerably from general practitioners, and pharmacists were overwhelmed by inappropriate alerts because of a lack of specificity of their drug-interaction systems. Substantial improvement of drug-interaction software systems is thus required at least in two important aspects, the suppression of inappropriate alerts and the tailoring to the needs of the user.

Citing Articles

Community pharmacist perceptions of drug-drug interactions.

Dahri K, Araujo L, Chen S, Bagri H, Walia K, Lau L Can Pharm J (Ott). 2023; 156(1):42-47.

PMID: 36686314 PMC: 9849923. DOI: 10.1177/17151635221140379.

Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.

Gedde-Dahl A, Spigset O, Molden E Eur J Clin Pharmacol. 2022; 78(10):1623-1632.

PMID: 35871665 PMC: 9482580. DOI: 10.1007/s00228-022-03364-5.

The Practice of the Community Pharmacists in Managing Potential Drug-Drug Interactions: A Simulated Patient Visits.

Hamadouk R, Albashair E, Mohammed F, Yousef B Integr Pharm Res Pract. 2022; 11:71-84.

PMID: 35313632 PMC: 8934170. DOI: 10.2147/IPRP.S355675.

Hospital Pharmacists' Perceptions and Decision-Making Related to Drug-Drug Interactions.

Bagri H, Dahri K, Legal M Can J Hosp Pharm. 2019; 72(4):288-294.

PMID: 31452540 PMC: 6699872.

Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions.

Beckett R, Stump C, Dyer M J Med Libr Assoc. 2019; 107(1):62-71.

PMID: 30598650 PMC: 6300238. DOI: 10.5195/jmla.2019.549.

References

Raschetti R, Morgutti M, Menniti-Ippolito F, Belisari A, Rossignoli A, Longhini P . Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol. 1999; 54(12):959-63. DOI: 10.1007/s002280050582. View

Bergk V, Gasse C, Schnell R, Haefeli W . Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol. 2004; 60(8):595-602. DOI: 10.1007/s00228-004-0812-6. View

Gurwitz J, Field T, Harrold L, Rothschild J, DeBellis K, Seger A . Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003; 289(9):1107-16. DOI: 10.1001/jama.289.9.1107. View

Jankel C, Fitterman L . Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf. 1993; 9(1):51-9. DOI: 10.2165/00002018-199309010-00005. View

Halkin H, Katzir I, Kurman I, Jan J, Malkin B . Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther. 2001; 69(4):260-5. DOI: 10.1067/mcp.2001.114228. View

Bergendal L, Friberg A, Schaffrath A . Potential drug--drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci. 1995; 17(5):152-7. DOI: 10.1007/BF01879709. View

Peng C, Glassman P, Marks I, Fowler C, Castiglione B, Good C . Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm. 2003; 9(6):513-22. PMC: 10437287. DOI: 10.18553/jmcp.2003.9.6.513. View

Durieux P . Electronic medical alerts--so simple, so complex. N Engl J Med. 2005; 352(10):1034-6. DOI: 10.1056/NEJMe058016. View

Chrischilles E, Fulda T, Byrns P, Winckler S, Rupp M, Chui M . The role of pharmacy computer systems in preventing medication errors. J Am Pharm Assoc (Wash). 2002; 42(3):439-48. DOI: 10.1331/108658002763316879. View

10.

Murphy J, Forrey R, Desiraju U . Community pharmacists' responses to drug-drug interaction alerts. Am J Health Syst Pharm. 2004; 61(14):1484-7. DOI: 10.1093/ajhp/61.14.1484. View

11.

Linnarsson R . Drug interactions in primary health care. A retrospective database study and its implications for the design of a computerized decision support system. Scand J Prim Health Care. 1993; 11(3):181-6. DOI: 10.3109/02813439308994827. View

12.

Huic M, Mucolic V, Vrhovac B, Francetic I, BAKRAN I, Giljanovic S . Adverse drug reactions resulting in hospital admission. Int J Clin Pharmacol Ther. 1994; 32(12):675-82. View

13.

Bjerrum L, Andersen M, Petersen G, Kragstrup J . Exposure to potential drug interactions in primary health care. Scand J Prim Health Care. 2003; 21(3):153-8. DOI: 10.1080/02813430310001806. View

14.

Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli W . Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther. 2004; 76(1):85-96. DOI: 10.1016/j.clpt.2004.02.009. View

15.

Rosholm J, Bjerrum L, Hallas J, Worm J, Gram L . Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. Dan Med Bull. 1998; 45(2):210-3. View

16.

Magnus D, Rodgers S, Avery A . GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther. 2002; 27(5):377-82. DOI: 10.1046/j.1365-2710.2002.00434.x. View

17.

McDonnell P, Jacobs M . Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002; 36(9):1331-6. DOI: 10.1345/aph.1A333. View

18.

Hansten P, Horn J, Hazlet T . ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc (Wash). 2001; 41(2):161-5. DOI: 10.1016/s1086-5802(16)31244-x. View

19.

Soumerai S, Lipton H . Computer-based drug-utilization review--risk, benefit, or boondoggle?. N Engl J Med. 1995; 332(24):1641-5. DOI: 10.1056/NEJM199506153322411. View

20.

Bjorkman I, Fastbom J, Schmidt I, Bernsten C . Drug-drug interactions in the elderly. Ann Pharmacother. 2002; 36(11):1675-81. DOI: 10.1345/aph.1A484. View